A 12 versus 6-week course of bacillus Calmette-Guerin prophylaxis for the treatment of high risk superficial bladder cancer

Journal of Urology

Volumn 157, Issue 2, 1997, Pages 487-491

  Gruenwald, Ilan E ^a   Stein, Avi ^a   Rashcovitsky, Roman ^a   Shifroni, Galia ^a   Lurie, Aharon ^a  

^a CARMEL MEDICAL CENTER   (Israel)

Author keywords

BCG vaccine; bladder neoplasms; carcinoma, transitional cell

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; TRANSITIONAL CELL CARCINOMA;

EID: 0031021801     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65183-8     Document Type: Article

References (15)

1. Heney, N. M.: Natural history of superficial bladder cancer: prognostic features and long term disease course. Urol. Clin. N. Amer., 19: 429, 1992.
2. Kavoussi, L. R., Torrence, R. J., Gillen, G. P., Hudson, M. A., Haaf, E. O., Dresner, M., Ratliff, T. L. and Catalona, W. J.: Results of 6 weekly intravesical bacillus Calmette-Guerin on the treatment of superficial bladder tumors. J. Urol., 139: 935, 1988.
3. Torrence, R. J., Kavoussi, L. R., Catalona, W. J. and Ratliff, T. L.: Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer. J. Urol., 139: 941, 1988.
4. Brosman, S. A.: Bacillus Calmette-Guerin immunotherapy: techniques and results. Urol. Clin. N. Amer., 19: 557, 1992.
5. Haaf, E. O., Dresner, S. M., Ratliff, T. L. and Catalona, W. J.: Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. J. Urol., 136: 820, 1986.
6. Badalament, R. A., Herr, W. H., Wong, G. Y., Gnecco, C., Pinsky, C. M., Whitmore, W. F., Jr., Fair, W. R. and Oettgen, H. F.: A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J. Clin. Oncol., 5: 441, 1987.
7. Heney, N. M., Ahmed, S., Flanagan, M. J., Frable, W., Corder, M. P., Hafermann, M. D. and Hawkins, I. R.: Superficial bladder cancer: progression and recurrence. National Bladder Cancer Collaborative Group A. J. Urol., 130: 1083, 1983.
8. Sarosdy, M. F. and Lamm, D. L.: Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J. Urol., 142: 719, 1989.
9. Soloway, M. S. and Perry, A.: Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who failed thiotepa and/or mitomycin C. J. Urol., 137: 871, 1987.
10. Herr, H. W., Pinsky, C. M., Whitmore, W. F., Jr., Sogani, P. C., Oettgen, H. F. and Melamed, M. R.: Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology, 25: 119, 1985.
11. Lamm, D. L.: Bacillus Calmette-Guerin immunotherapy for bladder cancer. J. Urol., 134: 40, 1985.
12. deKernion, J. B., Huang, M.-Y., Lindner, A., Smith, R. B. and Kaufman, J. J.: Management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin. J. Urol., 133: 598, 1985.
13. Brosman, S. A.: Experience with bacillus Calmette-Guérin in patients with superficial bladder cancer. J. Urol., 128: 27, 1982.
14. Coplen, D. E., Marcus, M. D., Myers, J. A., Ratliff, T. L. and Catalona, W. J.: Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guérin: analysis of possible predictors of response free of tumor. J. Urol., 144: 652, 1990.
15. Lamm, D. L.: Complications of bacillus Calmette-Guérin immunotherapy. Urol. Clin. N. Amer., 19: 565, 1992.